Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients

Table 3 The demographics and baseline characteristics of the patients

Characteristics	Brolucizumab N = 56	Aflibercept N = 58	P value
Age, years
Mean ± SD	72.05 ± 11.03	70.17 ± 9.02	0.32
Median	72.00	70.5
Min, max	51.00, 91.00	54.00, 91.00
Sex, n (%)			0.17
Male	37 (66.1)	30 (51.7)
Female	19 (33.9)	28 (48.3)
LogMAR BCVA
Mean ± SD	0.84 ± 0.32	0.87 ± 0.27	0.63
Min, max	0.28, 1.42	0.26, 1.30
CMT (µm)
Mean ± SD	355 ± 89.7	365.5 ± 55.78	0.46
Min, max	211.00, 598.00	265.00, 566.00
Presence of IRF n (%)	46 (82.1)	44 (75.9)	0.55
Presence of SRF n (%)	46 (82.1)	48 (82.8)	> 0.99
Presence of SHRM n (%)	24 (42.9)	31 (53.4)	0.35

Data presented as mean ± standard deviation or n (%)
BCVA Best corrected visual acuity, CMT Central macular thickness, IRF intraretinal fluid, SRF subretinal fluid, SHRM subretinal hyper-reflective material, SD standard deviation
*p-value < 0.05 for the t-test considered significant (none of the t-test found significance)
^#p-values < 0.05 for the chi-square test considered for significant correlation (none of the chi-square test found correlation)

ISSN: 2056-9920